Combo Treatment Provides Relief
A Canadian study of 2760 patients with asthma at 246 centers in 22countries found that combining an inhaled corticosteroid and a long-lastingbeta-2 agonist appeared to provide consistent relief for individuals withasthma. Specifically, there was a 45% lower exacerbation rate with thecombined budenoside/formoterol therapy. The treatment also loweredoverall severe exacerbation levels and delays in exacerbations requiringmedical attention, improved lung function, reduced awakenings at nightbecause of disease, and improved symptom control. (The findings werereported in the American Journal of Respiratory and Critical CareMedicine, January 2005).
Articles in this issue
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
- Evaluation of Pharmacist-Driven Penicillin Allergy Reconciliation
September 17th 2025
- Pharmacists Can Apply Their Expertise to the Medical Psilocybin Act
September 16th 2025
- From Curiosity to Clinical Impact: Shremo Msdi’s Path in Pharmacy Research
September 15th 2025